Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Exagen Inc. before investing.

In this article, we go over a few key elements for understanding Exagen Inc.’s stock price such as:

• Exagen Inc.’s current stock price and volume
• Why Exagen Inc.’s stock price changed recently
• Upgrades and downgrades for XGN from analysts
• XGN’s stock price momentum as measured by its relative strength

About Exagen Inc. (XGN)

Before we jump into Exagen Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company’s lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient’s blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Want to learn more about Exagen Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Exagen Inc..

Exagen Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Exagen Inc.’s stock price was $4.530.

Exagen Inc. is down 3% from its previous closing price of $4.670.

During the last market session, Exagen Inc.’s stock traded between $4.380 and $4.720. Currently, there are approximately 23.86 million shares outstanding for Exagen Inc..

Exagen Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Exagen Inc. Stock Price History

Exagen Inc.’s (XGN) price is currently down 2.58% so far this month.

During the month of July, Exagen Inc.’s stock price has reached a high of $5.110 and a low of $4.050.

Over the last year, Exagen Inc. has hit prices as high as $12.230 and as low as $2.590. Year to date, Exagen Inc.’s stock is down 25.49%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Exagen Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 31, 2026,, no analysts have changed their rating of Exagen Inc.’s stock over the last month.

Additionally, you'll want to evaluate Exagen Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Exagen Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Exagen Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Exagen Inc. (XGN) by visiting AAII Stock Evaluator.

Relative Price Strength of Exagen Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Exagen Inc. has a weighted four-quarter relative price strength of 5.21%, which translates to a Momentum Score of 71 and is considered to be Strong.

Want to learn more about how Exagen Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Exagen Inc. Stock Price: Bottom Line

As of July 31, 2026, Exagen Inc.’s stock price is $4.530, which is down 3% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Exagen Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.